Company Cuorips Inc.

4894

JP3266030000

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Annual profits - Rate of surprise

Sector Biopharmaceuticals

Market Closed - Japan Exchange Other stock markets 11:30:00 20/05/2024 am IST			5-day change	1st Jan Change
3,230 ^JPY	+9.98%		-6.78%	+39.16%

2023	Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2023.	CI
2023	Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 24-SEP-2023.	CI

Cuorips Inc is a Japan-based company mainly engaged in the development and commercialization of regenerative medical products and contract development and manufacturing organization (CDMO) business. The main product of the Company is human iPS cell-derived cardiomyocyte sheets. The Company provides regenerative medical products for the heart and other areas through in-house research, joint research with universities and other research institutions and major pharmaceutical companies. The Company operates CDMO business using CLiC-1, a commercial cell culture and processing facility with an integrated laboratory based on the Company's original design concept.

Number of employees: 43

JPY in Million	2022	Weight	2023	Weight	Delta
Contract Development and Manufacturing Organization Consulting Services 100.0 %	14	100.0 %	38	100.0 %	+175.12%

JPY in Million	2022	Weight	2023	Weight	Delta
Japan 100.0 %	14	100.0 %	38	100.0 %	+175.12%

Managers	Title	Age	Since
Takayuki Kusanagi CEO	Chief Executive Officer	65	01/20/01
Yoshiki Sawa CTO	Chief Tech/Sci/R&D Officer	68	01/21/01
Manabu Inoue ADM	Chief Administrative Officer	68	01/17/01
Kazuhiko Sakai SAM	Sales & Marketing	-	-

Members of the board	Title	Age	Since
Ryohei Shimazaki BRD	Director/Board Member	65	01/20/01
Takayuki Kusanagi CEO	Chief Executive Officer	65	01/20/01
Manabu Inoue ADM	Chief Administrative Officer	68	01/17/01
Tadashi Samejima BRD	Director/Board Member	64	01/22/01
Yoshiki Sawa CTO	Chief Tech/Sci/R&D Officer	68	01/21/01
Tetsuya Ohira BRD	Director/Board Member	56	01/21/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	7,968,116	5,670,259 ( 71.16 %)	15,756 ( 0.1977 %)	71.16 %

Name	Equities	%	Valuation
DAIICHI SANKYO CO., LTD. 12.55 %	1,000,000	12.55 %	22 M ¥
TERUMO CORPORATION 6.652 %	530,000	6.652 %	12 M ¥
JIC Venture Growth Investments Co. Ltd. 6.275 %	500,000	6.275 %	11 M ¥
Kyoto University Innovation Capital Co., Ltd. 4.238 %	337,700	4.238 %	7 M ¥
JAFCO Group Co. Ltd. (Private Equity) 3.811 %	303,700	3.811 %	7 M ¥
TAIKO PHARMACEUTICAL CO.,LTD. 3.765 %	300,000	3.765 %	7 M ¥
SBI HOLDINGS, INC. 3.176 %	253,100	3.176 %	6 M ¥
Nippon Venture Capital Corp. 2.711 %	216,000	2.711 %	5 M ¥
MITSUBISHI CORPORATION 2.100 %	167,333	2.100 %	4 M ¥
Manabu Inoue 1.770 %	141,050	1.770 %	3 M ¥

Name	Equities	%	Valuation
CUORIPS INC. 0.20%	15,600	0.20%	340,520 $

Cuorips, Inc.

507, Nihonbashi Life Science Bldg 3-11-5 Nihonbashi Honcho

103-0023, Tokyo

http://www.cuorips.co.jp

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Biopharmaceuticals

	1st Jan change	Capi.
CUORIPS INC.	+39.16%	150M
CSL LIMITED	-3.05%	90.45B
SAMSUNG BIOLOGICS CO.,LTD.	+3.95%	41.45B
BIOGEN INC.	-10.98%	33.57B
UCB	+60.58%	25.73B
BIOMARIN PHARMACEUTICAL INC.	-20.65%	14.73B
INCYTE CORPORATION	-8.93%	12.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.46%	11.7B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.05%	11.44B
SWEDISH ORPHAN BIOVITRUM AB	+5.17%	8.79B

Biopharmaceuticals